

Lytix Q3 2024 - First Patient in NeoLIPA

Redeye comments on Lytix' Q3 report. The main event since our last update is the start of the NeoLIPA trial, a study of LTX-315 as neoadjuvant melanoma treatment.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Lytix Q3 2024 - First Patient in NeoLIPA](#)